Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Vero Cell-Derived H5N1 Influenza Vaccine in Adults, Elderly, and Risk Groups
NCT00711295Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Aug 2008
- Primary completion
- Jul 2009
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of inactivated influenza vaccine (vero cell-derived), sponsored by Resilience Government Services. Started Aug 2008; status: completed.
02
Drugs
inactivated influenza vaccine (vero cell-derived)
Beyond the preview
Go deeper on NCT00711295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711295.